FDA Orders Recall of Blood Thinner Heparin
The FDA recently announced that the blood thinner Heparin may have been intentionally contaminated in order to reduce the cost of the drug. The FDA has said that Baxter's heparin may be so far linked to deaths associated with an adverse reaction to conta
(EMAILWIRE.COM, April 19, 2008 ) On April 15, 2008, the FDA announced that the blood thinner heparin, which has been associated with several deaths and allergic reactions, may have been intentionally contaminated in order to reduce the cost of the drug. The contaminated heparin was manufactured by Baxter International and is commonly used before certain types of surgery and during hemodialysis as a blood clotting preventative.
In addition, the FDA reported last week that there has been a substantial increase in the number of people who have died while taking the blood thinner. Its findings indicated that there have been 103 reports of heparin-associated deaths since January 1, 2007 and 91 of these were reported to the agency on or after January 1, 2008. Baxter and the FDA recalled several dosage types of heparin in February after receiving reports of adverse reactions including breathing difficulty, vomiting, excess sweating and a rapid decline in blood pressure. Baxter subsequently expanded the recall to include all remaining lots of its multi-dose, single dose and flush products.
The law firm of Cohen, Placitella & Roth is actively seeking referrals of cases that resulted in death or injury of individuals who were administered heparin. If you would like additional information concerning this litigation, please contact Stewart Cohen at 215-567-3500 or scohen@cprlaw.com.
http://www.cprlaw.com/Heparin-Recall-Contamination.cfm
In addition, the FDA reported last week that there has been a substantial increase in the number of people who have died while taking the blood thinner. Its findings indicated that there have been 103 reports of heparin-associated deaths since January 1, 2007 and 91 of these were reported to the agency on or after January 1, 2008. Baxter and the FDA recalled several dosage types of heparin in February after receiving reports of adverse reactions including breathing difficulty, vomiting, excess sweating and a rapid decline in blood pressure. Baxter subsequently expanded the recall to include all remaining lots of its multi-dose, single dose and flush products.
The law firm of Cohen, Placitella & Roth is actively seeking referrals of cases that resulted in death or injury of individuals who were administered heparin. If you would like additional information concerning this litigation, please contact Stewart Cohen at 215-567-3500 or scohen@cprlaw.com.
http://www.cprlaw.com/Heparin-Recall-Contamination.cfm
Contact Information:
Lawyer Central
Marc Lippman
Tel: 908-222-8848
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Lawyer Central
Marc Lippman
Tel: 908-222-8848
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |